Galecto Announces Clinical Collaboration with Roche for Phase II Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer

Galecto, Inc. announced that it has entered into a clinical trial supply agreement with Roche to explore the combination of GB1211, Galecto’s oral galectin-3 inhibitor, with Roche’s PD-L1 checkpoint inhibitor atezolizumab in Galecto’s planned Phase IIa trial in non-small-cell lung cancer